Pharmaceutical Research & Drug Development – Page 3

GLP readiness concerns during sponsor oversight – how to defend preclinical package

When exploring GLP readiness concerns, the initial phase involves identifying observable signals indicative of compliance failures. Symptoms may manifest in various forms, including:Click to read the full article.

Study design not regulator-aligned during regulatory submission prep – how to defend preclinical package

Identifying signals indicating a deviation in study design can be challenging yet essential. Symptoms may manifest in various forms, including:Click to read the full article.

Reproducibility gaps during study audit – how to defend preclinical package

Identifying symptoms indicative of reproducibility gaps is the first step in a thorough investigation. In a laboratory setting, these symptoms may manifest as variations in data that fail to replicate…

Species selection questioned during study audit – preventing clinical hold

Identifying symptoms or signals of inadequate species selection should be the first step in the investigation. Key signals to monitor include:Click to read the full article.

GLP readiness concerns during IND-enabling studies – FDA/EMA non-clinical expectations

Identifying early signals of GLP non-compliance can prevent significant setbacks in the drug development process. Common symptoms in the lab may include:Click to read the full article.

Reproducibility gaps during program hold risk review – CAPA for study design gaps

Detecting reproducibility gaps begins with identifying symptoms that may indicate underlying issues in study design or execution. The following signals are commonly observed in both preclinical studies and program risk…

Reproducibility gaps during sponsor oversight – FDA/EMA non-clinical expectations

Identifying symptoms of reproducibility gaps is the first step in addressing issues within preclinical studies. Symptoms may manifest in various ways:Click to read the full article.

Reproducibility gaps during sponsor oversight – FDA/EMA non-clinical expectations

Identifying reproducibility gaps begins with recognizing observable symptoms during laboratory work or data review. These signals can manifest in various forms:Click to read the full article.

Study design not regulator-aligned during program hold risk review – how to defend preclinical package

Identifying the presence of misalignment in study design requires awareness of several key symptoms or signals that can manifest in the laboratory or during reviews. These may include:Click to read…

Species selection questioned during regulatory submission prep – preventing clinical hold

Detecting early signals indicating potential issues with species selection is vital to preventing regulatory setbacks. Common symptoms include:Click to read the full article.

Dose justification weak during regulatory submission prep – CAPA for study design gaps

Recognizing the early warning signs of weak dose justification is crucial in preventing regulatory setbacks. Symptoms may include:Click to read the full article.

Study design not regulator-aligned during program hold risk review – regulatory deficiency risk analysis

In the context of preclinical studies, various symptoms may indicate a misalignment in study design during program hold risk reviews. These symptoms can arise during data collection, analysis, or regulatory…